GLP-1 & compounded medication availability in Ohio (2026)

Ohio is the strictest state among our first five, and the one where honest availability reporting matters most. Two of our ten lines ship here with caveats worth reading, one is paused pending review, two we do not carry in any state, and four research-peptide lines in our catalog elsewhere are blocked outright here under Ohio’s own 2025 peptide position. Read that section before you ask why. Every consequential row below traces to a cited source.

Restrictive state

Availability facts last reviewed: November 16, 2026

What actually ships to Ohio

Availability of all ten OrderlyMeds product lines in Ohio, with typical delivery times and notes
Product lineAvailable in Ohio?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Patient-specific prescriptions; see the regulator section for Ohio’s 2025 guidance.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same patient-specific basis as the row above.
NAD+ Yes 8–10 business days No Ohio-specific caveat identified.
Sermorelin No N/A Paused pending line-level review of Ohio’s 2025 peptide guidance.
Glutathione No N/A Not in the OrderlyMeds catalog anywhere.
BPC-157 No N/A In our catalog elsewhere, but blocked for Ohio under the 2025 state position cited below.
TB-500 No N/A In our catalog elsewhere; blocked for Ohio by the same state position.
KPV No N/A Not carried, injectables only. See the peptide sections.
Epitalon No N/A In our catalog elsewhere; blocked for Ohio by the same state position.
MOTS-c No N/A In our catalog elsewhere; blocked for Ohio by the same state position, its own federal record notwithstanding.

Seven No rows is what honesty looks like in Ohio right now. Facts reviewed November 16, 2026; the sermorelin pause lifts when its review completes, the four peptide blocks lift only if Ohio’s own position moves.

Research peptides and Ohio: two layers of facts

For Ohio there are two distinct layers, and layer two wins. Layer one is our catalog: OrderlyMeds carries BPC-157, TB-500, Epitalon and MOTS-c as compounded injectables elsewhere, and carries KPV in no state. Layer two is Ohio-specific and cited just below: the state’s own 2025 position on peptide compounding, which overrides our catalog and the federal pathway each section describes. None of the four ship to an Ohio address.

In its July 2025 guidance, the State of Ohio Board of Pharmacy stated that compounding investigational peptides is prohibited for pharmacies dispensing into Ohio — a state-level position that applies regardless of the federal enforcement-discretion pathway described in the sections below. Source: State of Ohio Board of Pharmacy.

BPC-157 in Ohio

In our catalog as a compounded injectable elsewhere; blocked for Ohio under the state position on investigational peptides cited above.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Ohio

Carried by OrderlyMeds as a compounded injectable elsewhere; blocked for Ohio by the same cited state position on investigational peptides.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Ohio

Outside our formulary everywhere, since it is not compounded as an injectable, and subject to the Ohio position cited above.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Ohio

Dispensed by us as a compounded injectable elsewhere; blocked for Ohio under the same cited state position.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Ohio

Carried by us as a compounded injectable elsewhere, but covered by the same cited Ohio state position as the other three and blocked here regardless. Its own federal record, below, differs from theirs — that difference does not reach Ohio’s state-level position.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Ohio’s pharmacy regulators say, on the strictest page in this pilot

Ohio’s regulators have been the most active in the country on compounded GLP-1s and peptides since 2025. That does not make Ohio a no-go state. It makes the details decisive. The three cited positions below are the ones that shape what OrderlyMeds can and cannot send to an Ohio address.

July 2025 board guidance: compounding copies of FDA-approved semaglutide and tirzepatide products is not permitted following shortage resolution, except patient-specific 503A compounding where a prescriber documents a clinically significant difference for that individual patient. Source: State of Ohio Board of Pharmacy.

The same July 2025 guidance states that compounding investigational peptides is prohibited for pharmacies dispensing into Ohio -- a state-level position that applies regardless of HHS's October 2026 federal enforcement-discretion policy. Source: State of Ohio Board of Pharmacy.

Ohio has pursued active enforcement on compounded GLP-1 copies, including pharmacy license suspensions and attorney-general correspondence to telehealth sellers. Source: State of Ohio Board of Pharmacy.

What we do with all that: OrderlyMeds dispenses compounded GLP-1s to Ohio only under patient-specific prescriptions written for an individual clinical need, the pathway Ohio’s own guidance preserves; we do not dispense BPC-157, TB-500, Epitalon, or MOTS-c to an Ohio address at all, because the cited investigational-peptide position above leaves no patient-specific carve-out the way the GLP-1 guidance does; and we have marked sermorelin unavailable here until its status under the peptide guidance is individually reviewed, rather than assuming an answer we would like. If Ohio’s position moves, this page moves with the data feed behind it, in either direction.

Ohio availability FAQs

Can I still get compounded semaglutide in Ohio?

Yes, under a patient-specific prescription written for your individual clinical needs, which is the pathway Ohio’s 2025 guidance preserves. The cited detail sits in the regulator section above.

Why is sermorelin marked unavailable in Ohio when nearby states have it?

Because we would rather under-promise: Ohio’s 2025 peptide guidance needs a line-level review before we list sermorelin as shippable there. The row flips when the review says so, not before.

Can Ohio residents order BPC-157 or TB-500 anywhere?

No. We carry both, along with Epitalon and MOTS-c, as compounded injectables in states where our catalog reaches — but Ohio’s own cited 2025 state position on investigational peptides, stated in full above, blocks all four regardless of catalog status elsewhere or the federal pathway.

Is delivery to Ohio slower because of the extra rules?

No, the published 8–10 business-day window applies to Ohio like everywhere else.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone